Molecular Profile Detail

Profile Name KRAS mutant
Gene Variant Detail

KRAS mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant Advanced Solid Tumor sensitive MK2206 + Romidepsin Preclinical Actionable In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708) detail...
KRAS mutant non-small cell lung carcinoma sensitive Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583). 26343583
KRAS mutant non-small cell lung carcinoma sensitive Trametinib Phase I Actionable In a Phase I trial, two non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). 22805291
KRAS mutant colorectal adenocarcinoma no benefit Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin Phase Ib/II Actionable In a Phase Ib/II trial, the combination of Sprycel (dasatinib) and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma harboring KRAS codon 12/13 mutations, with no responses and a median time to treatment failure of 2.0 months (PMID: 28280091; NCT00501410). 28280091
KRAS mutant non-small cell lung carcinoma no benefit Erlotinib + MK2206 Phase II Actionable In a Phase II trial, Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147). 27480147
KRAS mutant Advanced Solid Tumor predicted - sensitive PF-00477736 + PF3644022 Preclinical - Cell line xenograft Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595). 26140595
KRAS mutant non-small cell lung carcinoma predicted - sensitive XMT-1536 Preclinical - Pdx Actionable In a preclinical study, XMT-1536 induced tumor regression in patient-derived-xenograft models of of non-small cell lung cancer harboring KRAS mutations (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194). detail...
KRAS mutant Advanced Solid Tumor predicted - sensitive BGB-283 Phase I Actionable In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive Navitoclax + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Navitoclax (ABT-263) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant melanoma predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant pancreatic cancer sensitive GDC-0980 + PD-0325901 Preclinical Actionable In a preclinical study, the addition of PD-0325901 to treatment with GDC-0980 and inhibited GDC-0980-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic cancer cells harboring KRAS mutations in culture (PMID: 25673820). 25673820
KRAS mutant colorectal cancer sensitive Trametinib Phase I Actionable In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291). 22805291
KRAS mutant Advanced Solid Tumor no benefit CC-90003 Phase I Actionable In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive Dasatinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant colon cancer sensitive AZ-TAK1 + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129). 27655129
KRAS mutant Advanced Solid Tumor resistant Everolimus Clinical Study - Cohort Actionable In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172). 20664172
KRAS mutant colorectal cancer predicted - sensitive LSN3074753 Preclinical - Pdx Actionable In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205). 28611205
KRAS mutant non-small cell lung carcinoma predicted - sensitive Atezolizumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients (PMID: 29270615). 29270615
KRAS mutant pancreatic ductal adenocarcinoma sensitive Saracatinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant pancreatic ductal adenocarcinoma sensitive Saracatinib + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant acute myeloid leukemia predicted - resistant Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, KRAS mutations correlated with resistance to Xalkori (crizotinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). 30333627
KRAS mutant breast cancer decreased response PI-273 Preclinical - Cell culture Actionable In a preclinical study, breast cancer cell lines harboring RAS mutations, including KRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273 in culture (PMID: 28827373). 28827373
KRAS mutant pancreatic cancer decreased response Pictilisib Preclinical - Cell line xenograft Actionable In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903). 22952903
KRAS mutant colorectal cancer predicted - resistant Cetuximab Case Reports/Case Series Actionable In a clinical case study, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) treatment in a patient with metastatic colorectal cancer (PMID: 24304820). 24304820
KRAS mutant pancreatic cancer no benefit Gemcitabine + Rigosertib Phase II Actionable In a Phase II study, Estybon (rigosertib) in combination with, gemcitabine, did not demonstrate increased efficacy over gemcitabine alone and there was no correlation of reponse with Kras mutational status in pancreatic patients (PMID: 26091808). 26091808
KRAS mutant non-small cell lung carcinoma sensitive KPT-185 Preclinical - Cell culture Actionable In a preclinical study, KPT-185 resulted in greater apoptotic activity and decreased cell viability in non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations compared to NSCLC cell lines with wild-type KRAS, suggesting a synthetic lethal effect via XPO1 inhibition (PMID: 27680702). 27680702
KRAS mutant non-small cell lung carcinoma sensitive Selumetinib + SHP099 Preclinical - Cell culture Actionable In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation was sensitive to the combination treatment of Selumetinib (AZD6244) and SHP099, demonstrating reduced cell viability and decreased colony formation in culture compared to either agent alone (PMID: 30045908). 30045908
KRAS mutant pancreatic ductal adenocarcinoma sensitive Nilotinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant gastric adenocarcinoma sensitive Selumetinib Preclinical Actionable In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174). 24935174
KRAS mutant colorectal cancer sensitive DEL-22379 Preclinical Actionable In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534). 26267534
KRAS mutant non-small cell lung carcinoma sensitive Sorafenib Phase II Actionable In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737). 23224737
KRAS mutant non-small cell lung carcinoma sensitive Sorafenib Phase II Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147). 27480147
KRAS mutant non-small cell lung carcinoma sensitive Sorafenib Phase III Actionable In a Phase III trial, treatment with Nexavar (sorafenib) resulted in a longer progression free survival in patients with KRAS-mutant non-small cell lung cancer when compared to placebo, however, overall survival was similar between the two arms (PMID: 26743856). 26743856
KRAS mutant colorectal cancer no benefit Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920). 26341920
KRAS mutant non-small cell lung carcinoma predicted - sensitive Erlotinib + IRX4204 Preclinical - Cell culture Actionable In a preclinical study, the combination of Tarceva (erlotinib) and IRX4204 inhibited proliferation of non-small cell lung cancer cell lines in culture, including cell lines harboring KRAS mutations, and resulted in increased inhibition of proliferation and Src, p-AKT, and ribosomal S6 compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14095)). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive Neratinib + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant pancreatic cancer predicted - sensitive GI-4000 Phase I Actionable In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 24372276, PMID: 25585100). 24372276 25585100
KRAS mutant Advanced Solid Tumor sensitive GDC-0623 Preclinical - Cell line xenograft Actionable In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108). 23934108
KRAS mutant pancreatic ductal adenocarcinoma sensitive SCH772984 + Temsirolimus Preclinical - Cell culture Actionable In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant non-small cell lung carcinoma predicted - sensitive Pemetrexed + Trametinib Phase I Actionable In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate (ORR) of 17% (4/23, all partial responses), and stable disease in 48% (11/23) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 11% (2/19) in patients with wild-type or unknown KRAS status (PMID: 27876675). 27876675
KRAS mutant colorectal cancer predicted - sensitive Ixabepilone + Sunitinib Phase I Actionable In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients, most of whom harbored KRAS mutations (PMID: 26864210). 26864210
KRAS mutant pancreatic ductal adenocarcinoma sensitive BMS-754807 + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant non-small cell lung carcinoma no benefit MK2206 + Selumetinib Phase II Actionable In a Phase II trial, Selumetinib (AZD6244) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (49%, 24/49) and KRAS mutated (62%, 13/21) patients with advanced non-small cell lung carcinoma (PMID: 27480147). 27480147
KRAS mutant urinary bladder cancer predicted - sensitive PF-00477736 + PF3644022 Preclinical - Cell line xenograft Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595). 26140595
KRAS mutant lung carcinoma sensitive AZD4785 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cell lines harboring KRAS mutations, and anti-tumor activity in cell line xenograft models (PMID: 28615361). 28615361
KRAS mutant ovarian cancer sensitive Alpelisib + Binimetinib Phase I Actionable In a Phase I clinical trial, Alpelisib (BYL719), in combination with Binimetinib (MEK162), demonstrated safety and preliminary efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive PF-04691502 + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521
KRAS mutant colorectal cancer sensitive Palbociclib + Trametinib Preclinical - Pdx Actionable In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in objective response in PDX models of colorectal cancer cells harboring KRAS mutations (PMID: 26369631). 26369631
KRAS mutant non-small cell lung carcinoma predicted - sensitive BGB-283 Phase I Actionable In a Phase I trial, BGB-283 resulted in partial response in 1 non-small cell lung carcinoma patient harboring KRAS mutation, who remained on treatment for over 572 days (AACR Annual Meeting, Apr 2016, abstract # CT005). detail...
KRAS mutant melanoma predicted - sensitive MLN2480 Preclinical Actionable In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146). detail...
KRAS mutant stomach cancer decreased response BAY1082439 Preclinical Actionable In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674). detail...
KRAS mutant thyroid cancer sensitive HM95573 Preclinical - Cell culture Actionable In a preclinical study, HM95573 inhibited growth of KRAS mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607). detail...
KRAS mutant colorectal cancer predicted - sensitive Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin Phase II Actionable In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738). 26766738
KRAS mutant non-small cell lung carcinoma predicted - sensitive PF-04691502 Preclinical - Cell line xenograft Actionable In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219). 21750219
KRAS mutant non-small cell lung carcinoma sensitive Aurora Kinase Inhibitor II Preclinical - Cell culture Actionable In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935). 26842935
KRAS mutant pancreatic adenocarcinoma sensitive BI-847325 Preclinical Actionable In a preclinical study, BI-847325 promoted tumor regression in mutant KRAS pancreatic adenocarcinoma models (Cancer Res 2012;72(8 Suppl):Abstract nr 1919). detail...
KRAS mutant Advanced Solid Tumor sensitive Alpelisib + Binimetinib Phase Ib/II Actionable In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051). detail...
KRAS mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Phase I Actionable In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). 28039262
KRAS mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients (PMID: 29270615). 29270615
KRAS mutant stomach cancer resistant Poziotinib Preclinical Actionable In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821). 21306821
KRAS mutant colorectal cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Ramucirumab Phase III Actionable In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855). 25877855
KRAS mutant lung cancer predicted - sensitive DT-061 Preclinical - Pdx & cell culture Actionable In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649). 28504649
KRAS mutant lung cancer sensitive Ponatinib + Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794). 27338794
KRAS mutant stomach carcinoma predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant non-small cell lung carcinoma no benefit Carboplatin + Erlotinib + Paclitaxel Phase III Actionable In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828). 16043828
KRAS mutant colorectal cancer no benefit Regorafenib Phase II Actionable In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654). 30120161
KRAS mutant colorectal cancer no benefit Regorafenib Phase III Actionable In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680). 30190299
KRAS mutant colon adenocarcinoma not applicable N/A Phase III Emerging In a post-hoc analysis of a Phase III trial, KRAS mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that KRAS mutations may serve as a future prognostic biomarker in this patient population (PMID: 26768652). 26768652
KRAS mutant non-small cell lung carcinoma predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive Panobinostat + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant colorectal cancer predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant non-small cell lung carcinoma sensitive Abemaciclib Phase I Actionable In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383). 27217383
KRAS mutant thyroid medullary carcinoma sensitive Cabozantinib Phase III Actionable In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386). 27525386
KRAS mutant colorectal cancer sensitive Irinotecan + Reolysin Preclinical - Cell culture Actionable In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549). 24798549
KRAS mutant ovarian cancer sensitive OSI-027 Preclinical - Cell line xenograft Actionable In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091). 21673091
KRAS mutant lung squamous cell carcinoma sensitive Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583). 26343583
KRAS mutant Advanced Solid Tumor predicted - sensitive APS-2-79 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948). 27556948
KRAS mutant Advanced Solid Tumor sensitive Metformin Preclinical - Cell line xenograft Actionable In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793). 23877793
KRAS mutant pancreatic ductal adenocarcinoma sensitive Dinaciclib + MK2206 Preclinical - Pdx Actionable In a preclinical study, the combination of Dinaciclib (SCH 727965) and MK-2206 inhibited tumor growth and metastasis in KRAS-mutant patient-derived xenograft models of pancreatic ductal adenocarcinoma, with some models achieving complete response (PMID: 25931518). 25931518
KRAS mutant Advanced Solid Tumor no benefit CH5132799 Preclinical Actionable In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814). 22159814
KRAS mutant stomach cancer sensitive Buparlisib + Tyrphostin B42 Preclinical Actionable In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814). 22159814
KRAS mutant colorectal cancer sensitive BEZ235 Preclinical Actionable In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782). 23475782
KRAS mutant non-small cell lung carcinoma sensitive BI2536 Preclinical Actionable In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303). 26597303
KRAS mutant non-small cell lung carcinoma sensitive HM95573 Preclinical - Cell line xenograft Actionable In a preclinical study, HM95573 inhibited growth of KRAS mutant non-small cell lung cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607). detail...
KRAS mutant lung adenocarcinoma no benefit Salirasib Phase II Actionable In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063). 21847063
KRAS mutant endometrial cancer predicted - sensitive BGB-283 Phase I Actionable In a Phase I trial, BGB-283 resulted in partial response in 1 endometrial cancer patient harboring harboring KRAS mutation, who remained on treatment for over 456 days (AACR Annual Meeting, Apr 2016, abstract # CT005). detail...
KRAS mutant colorectal cancer no benefit RO4987655 Phase I Actionable In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927). 24947927
KRAS mutant colorectal cancer sensitive HM95573 Preclinical - Cell line xenograft Actionable In a preclinical study, HM95573 inhibited growth of KRAS mutant colorectal cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607). detail...
KRAS mutant pancreatic adenocarcinoma predicted - sensitive PF-00477736 + PF3644022 Preclinical - Patient cell culture Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595). 26140595
KRAS mutant multiple myeloma resistant Trametinib Preclinical Actionable In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583). 26343583
KRAS mutant pancreatic ductal adenocarcinoma sensitive Everolimus + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant endometrial cancer no benefit Temsirolimus Phase II Actionable In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228). 27016228
KRAS mutant colon cancer resistant GDC0879 Preclinical - Cell culture Actionable In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360). 19276360
KRAS mutant pancreatic ductal adenocarcinoma sensitive Ridaforolimus + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant non-small cell lung carcinoma no benefit Afatinib Guideline Actionable KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org). detail...
KRAS mutant colorectal cancer predicted - resistant SHP099 Preclinical Actionable In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227). 27362227
KRAS mutant lung cancer predicted - sensitive PF-00477736 + PF3644022 Preclinical - Cell line xenograft Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595). 26140595
KRAS mutant acute myeloid leukemia predicted - resistant TAE684 Preclinical - Patient cell culture Actionable In a preclinical study, KRAS mutations correlated with resistance to TAE684 in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). 30333627
KRAS mutant pancreatic ductal adenocarcinoma sensitive Pictilisib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant non-small cell lung carcinoma no benefit Osimertinib Guideline Actionable KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org). detail...
KRAS mutant non-small cell lung carcinoma predicted - sensitive TVB-2640 Phase I Actionable In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)). detail...
KRAS mutant non-small cell lung carcinoma predicted - sensitive Docetaxel + Trametinib Phase I Actionable In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 24% (6/25, all partial responses), and stable disease in 36% (9/25) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 18% (4/22) in patients with wild-type or unknown KRAS status (PMID: 27876675). 27876675
KRAS mutant colorectal cancer predicted - sensitive Atezolizumab + Cobimetinib Phase I Actionable In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140). detail...
KRAS mutant colon cancer sensitive AZ-TAK1 Preclinical - Cell culture Actionable In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129). 27655129
KRAS mutant pancreatic ductal adenocarcinoma sensitive Midostaurin + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant pancreatic cancer predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant hepatocellular carcinoma sensitive Refametinib + Sorafenib Phase II Actionable In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897). 25294897
KRAS mutant hepatocellular carcinoma sensitive Refametinib + Sorafenib Phase II Actionable In a Phase II trial, Refametinib (BAY86-9766) and Nexavar (sorafenib) combination treatment resulted in an objective response rate of 6.3% (1/16), a disease control rate of 43.8% (7/16), an overall survival of 12.7 months, and a progression-free survival of 1.5 months in patients unresectable or metastatic hepatocellular carcinoma harboring RAS (NRAS and KRAS) mutations (PMID: 29950351; NCT01915602). 29950351
KRAS mutant pancreatic ductal adenocarcinoma sensitive Ralimetinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant non-small cell lung carcinoma predicted - sensitive Nivolumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients (PMID: 29270615). 29270615
KRAS mutant non-small cell lung carcinoma predicted - sensitive Nivolumab Phase III Actionable In a Phase III trial, non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated an objective response rate (ORR) of 18.2% (2/11) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation (PMID: 29773717; NCT01673867). 29773717
KRAS mutant Advanced Solid Tumor predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126). detail...
KRAS mutant colorectal cancer sensitive CI-1040 Preclinical Actionable In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556). 19372556
KRAS mutant colorectal cancer sensitive Cetuximab + LSN3074753 Preclinical - Pdx Actionable In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205). 28611205
KRAS mutant pancreatic ductal carcinoma resistant Trametinib Preclinical Actionable In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583). 26343583
KRAS mutant endometrial cancer resistant Trametinib Preclinical Actionable In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583). 26343583
KRAS mutant non-small cell lung carcinoma predicted - sensitive Paclitaxel + TVB-2640 Phase I Actionable In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)). detail...
KRAS mutant Advanced Solid Tumor sensitive CUDC-907 Preclinical - Cell line xenograft Actionable In a preclinical study, CUDC-907 induced apoptosis and cell cycle arrest in several human solid tumor and hematological cancer cell lines in culture and inhibited tumor growth in tumor cell line xenograft models, including those harboring KRAS mutations (PMID: 22693356). 22693356
KRAS mutant lung cancer sensitive BGJ398 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant pancreatic ductal adenocarcinoma sensitive MK2206 + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant Advanced Solid Tumor predicted - sensitive Cobimetinib + Ipatasertib Phase I Actionable In a Phase I trial, the combination of Ipatasertib (GDC-0068) and Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Cancer Res, October 1, 2014 74; CT328). detail...
KRAS mutant pancreatic cancer sensitive Ponatinib + Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant pancreatic ductal adenocarcinoma sensitive Gedatolisib + PD-0325901 Preclinical - Cell culture Actionable In a preclinical study, the addition of combination PD-0325901 to treatment with Gedatolisib (PF-05212384) and PD-0325901 inhibited Gedatolisib (PF-05212384)-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic ductal adenocarcinoma cell lines harboring KRAS mutations in culture (PMID: 25673820). 25673820
KRAS mutant pancreatic ductal adenocarcinoma sensitive Pictilisib + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant lung cancer no benefit Afatinib + Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant pancreatic ductal adenocarcinoma sensitive AZD8186 + SCH772984 Preclinical - Pdx & cell culture Actionable In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant colorectal cancer no benefit Fluorouracil + Irinotecan + Leucovorin + Simtuzumab Phase II Actionable In a Phase II trial, combination of Simtuzumab (GS-6634) with FOLFIRI did not improve median progression-free survival (5.5 vs 5.8 months) or median overall survival (11.4 vs 16.3 months) compared to FOLFIRI with placebo in patients with KRAS mutant colorectal cancer (PMID: 28246207; NCT01479465). 28246207
KRAS mutant pancreatic ductal adenocarcinoma sensitive AZD8055 + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant colon cancer predicted - sensitive Luminespib Preclinical - Cell line xenograft Actionable In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with Luminespib (AUY922) in culture and in xenograft models (PMID: 26832792). 26832792
KRAS mutant non-small cell lung carcinoma no benefit Gefitinib Guideline Actionable KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org). detail...
KRAS mutant non-small cell lung carcinoma resistant GDC0879 Preclinical - Cell culture Actionable In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360). 19276360
KRAS mutant non-small cell lung carcinoma sensitive SH-1242 Preclinical Actionable In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561). 26645561
KRAS mutant colon cancer predicted - sensitive OPB-111077 Phase I Actionable In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive SCH772984 Preclinical - Pdx Actionable In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216). 26725216
KRAS mutant colorectal cancer no benefit Cetuximab + Fluorouracil + Irinotecan + Leucovorin Phase III Actionable In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843). 25605843
KRAS mutant pancreatic ductal adenocarcinoma predicted - sensitive BEZ235 + PD-0325901 Preclinical - Cell culture Actionable In a preclinical study, the addition of PD-0325901 to treatment with BEZ235 inhibited BEZ235-enhanced ERK activation, and the combination resulted in increased inhibition of cell proliferation in KRAS-mutant pancreatic ductal adenocarcinoma cell lines in culture compared to either agent alone (PMID: 25673820). 25673820
KRAS mutant non-small cell lung carcinoma no benefit Erlotinib Guideline Actionable KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org). detail...
KRAS mutant non-small cell lung carcinoma no benefit Erlotinib Phase II Actionable In a Phase II trial, Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147). 27480147
KRAS mutant colorectal cancer sensitive Pimasertib + SAR245409 Phase Ib/II Actionable In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive SCH772984 + Vistusertib Preclinical - Cell culture Actionable In a preclinical study, Vistusertib (AZD2014) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant pancreatic cancer predicted - sensitive Trametinib Phase I Actionable In a Phase I trial, a pancreatic cancer patient harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). 22805291
KRAS mutant Advanced Solid Tumor no benefit Cobimetinib + Duligotuzumab Phase I Actionable In a Phase I trial, Duligotuzumab (MEHD7945A) and Cotellic (cobimetinib) combination therapy demonstrated limited safety and efficacy, with stable disease as best response in 41% (9/22) of patients with KRAS-mutant solid tumors (PMID: 28592615; NCT01986166). 28592615
KRAS mutant lung adenocarcinoma predicted - sensitive PF-00477736 + PF3644022 Preclinical - Patient cell culture Actionable In a preclinical study, primary tumor cells isolated from lung adenocarcinoma patients harboring KRAS mutations demonstrated increased sensitivity to Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment in culture compared to cells lacking KRAS or BRAF mutations (PMID: 26140595). 26140595
KRAS mutant ovarian cancer sensitive CI-1040 Preclinical - Cell line xenograft Actionable In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267). 19018267
KRAS mutant non-small cell lung carcinoma no benefit Docetaxel + Selumetinib Phase II Actionable In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175). 23200175
KRAS mutant non-small cell lung carcinoma no benefit Docetaxel + Selumetinib Phase III Actionable In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) did not significantly improve median progression-free survival (3.9 vs 2.8 months), median overall survival (8.7 vs 7.9 months), and overall response rate (20.1% vs 13.7%) compared to placebo in KRAS-mutant non-small cell lung cancer patients (PMID: 28492898). 28492898
KRAS mutant lung adenocarcinoma decreased response Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS mutant lung cancer sensitive Crizotinib + Trametinib Preclinical - Cell culture Actionable In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) demonstrated additive effect at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant cervix carcinoma predicted - sensitive KO-947 Preclinical - Pdx Actionable In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168). detail...
KRAS mutant non-small cell lung carcinoma sensitive RO4987655 Phase I Actionable In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927). 24947927
KRAS mutant pancreatic ductal adenocarcinoma sensitive Ipatasertib + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant leukemia predicted - sensitive Trametinib Phase Ib/II Actionable In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive Danusertib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant pancreatic cancer sensitive Pictilisib + Selumetinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903). 22952903
KRAS mutant pancreatic cancer predicted - sensitive PF-00477736 + PF3644022 Preclinical - Cell line xenograft Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595). 26140595
KRAS mutant colon cancer decreased response Ponatinib + Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant colon cancer predicted - sensitive PF-00477736 + PF3644022 Preclinical - Cell line xenograft Actionable In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595). 26140595
KRAS mutant colorectal cancer decreased response Bevacizumab Clinical Study - Cohort Actionable In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442). 23828442
KRAS mutant Advanced Solid Tumor no benefit MLN1117 Preclinical Actionable In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501). detail...
KRAS mutant pancreatic ductal adenocarcinoma sensitive OSI-027 + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
KRAS mutant lung adenocarcinoma decreased response Binimetinib Preclinical - Cell culture Actionable In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS mutant Advanced Solid Tumor resistant AZD8835 Preclinical Actionable In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307). 26839307
KRAS mutant pancreatic ductal adenocarcinoma sensitive AZD8186 + Ulixertinib Preclinical - Patient cell culture Actionable In a preclinical study, AZD8186 and BVD-523 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26725216). 26725216
KRAS mutant lung adenocarcinoma sensitive AT13148 Preclinical Actionable In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553). 22781553
KRAS mutant Advanced Solid Tumor sensitive NS1 Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802). 27820802
KRAS mutant pancreatic adenocarcinoma sensitive Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583). 26343583
KRAS mutant colorectal cancer predicted - sensitive Binimetinib Phase I Actionable In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546). 28152546
KRAS mutant non-small cell lung carcinoma sensitive Volasertib Preclinical Actionable In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303). 26597303
KRAS mutant non-small cell lung carcinoma not applicable N/A Guideline Prognostic KRAS mutations are associated with shorter survival in patients with non-small cell lung carcinoma (NCCN.org). detail...
KRAS mutant non-small cell lung carcinoma sensitive Panulisib Preclinical - Cell line xenograft Actionable In a preclinical study, Panulisib (P7170) demonstrated inhibition of tumor growth in cell line xenograft models of non-small cell lung cancer harboring KRAS mutations (Cancer Res 2012, 72(8 Suppl), Abstract #3759). detail...
KRAS mutant lung cancer sensitive AZD4547 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant lung cancer no benefit Gefitinib + Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794). 27338794
KRAS mutant lung adenocarcinoma sensitive GI-4000 Phase II Actionable In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103). 25044103
KRAS mutant colorectal cancer sensitive Reolysin Preclinical - Cell culture Actionable In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549). 24798549
KRAS mutant Advanced Solid Tumor sensitive BI-847325 Phase I Actionable In a Phase I trial, BI-847325 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Mol Cancer Ther 2013;12(11 Suppl):B281). detail...
KRAS mutant lung adenocarcinoma sensitive Trametinib Preclinical Actionable In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583). 26343583
KRAS mutant lung adenocarcinoma predicted - sensitive unspecified PD-1 antibody Clinical Study - Cohort Actionable In a clinical study, lung adenocarcinoma patients harboring a KRAS mutation demonstrated an intermediate objective response rate (28.6% vs 35.7% vs 7.4%), PFS (2.7mo vs 3.0 vs 1.8), and OS (16.1mo vs 16.0 vs 6.4) compared to patients with co-occurring KRAS and TP53 mutations, and patients with co-occurring KRAS and STK11 mutations when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717). 29773717
KRAS mutant Advanced Solid Tumor sensitive Trametinib Phase I Actionable In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291). 22805291
KRAS mutant gastric adenocarcinoma conflicting Trametinib Preclinical Actionable In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583). 26343583
KRAS mutant Advanced Solid Tumor predicted - sensitive Gedatolisib Preclinical - Cell culture Actionable In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073). 21325073
KRAS mutant Advanced Solid Tumor sensitive RAF709 Phase I Actionable In a preclinical study, cancer cell lines harboring KRAS mutations demonstrated increased sensitivity to RAF709 compared to KRAS wild-type cells in culture (PMID: 29343524). 29343524
KRAS mutant pancreatic ductal adenocarcinoma sensitive Linsitinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216). 26725216
Clinical Trial Phase Therapies Title Recruitment Status
NCT03600701 Phase II Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Recruiting
NCT01750281 Phase II Docetaxel Docetaxel + Selumetinib Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Active, not recruiting
NCT03520842 Phase II Methotrexate + Regorafenib Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Suspended
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Recruiting
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Olaparib + Vistusertib Capivasertib + Olaparib AZD6738 + Olaparib OLAParib COmbinations (OLAPCO) Recruiting
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer Active, not recruiting
NCT03004105 Phase II Durvalumab + Selumetinib MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT02607813 Phase I LXH 254 + PDR001 LXH 254 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Recruiting
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Recruiting
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Recruiting
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting
NCT01877083 Phase II Lenvatinib Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn
NCT01907815 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Terminated
NCT01986166 Phase I Cobimetinib + Duligotuzumab A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS Completed
NCT01951690 Phase II Defactinib Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Completed
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed
NCT02258607 Phase I Momelotinib Momelotinib + Trametinib Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase Terminated
NCT03377361 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Recruiting
NCT03808558 Phase II TVB-2640 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Not yet recruiting
NCT03317119 Phase I Trametinib + trifluridine/tipiracil hydrochloride Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting
NCT03756818 Phase I Paclitaxel + TAK-659 TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Recruiting
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT03299088 Phase I Pembrolizumab + Trametinib Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Recruiting
NCT03829319 Phase III Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Carboplatin + Pembrolizumab + Pemetrexed Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Cisplatin + Pembrolizumab + Pemetrexed Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) Recruiting
NCT03732703 Phase Ib/II Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) Recruiting
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Recruiting
NCT03681483 Phase I RO5126766 RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Recruiting
NCT02079740 Phase Ib/II Navitoclax + Trametinib Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Active, not recruiting
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Recruiting
NCT02248805 Phase I MGD007 Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma Completed
NCT01973868 Phase I Cetuximab + Regorafenib Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination Completed
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Recruiting
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting
NCT02243917 Phase I CB-5083 A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors Terminated
NCT02417701 Phase II Sapanisertib TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer Recruiting
NCT03704688 Phase Ib/II Ponatinib + Trametinib Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Recruiting
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting
NCT02152631 Phase III Erlotinib Abemaciclib A Study of LY2835219 in Participants With Previously Treated Lung Cancer Active, not recruiting
NCT02296242 Phase Ib/II Ulixertinib Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Completed
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT01915602 Phase II Refametinib + Sorafenib Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed
NCT03065387 Phase I Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib Study of the Pan-ERBB InhibStudy of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation Recruiting
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Active, not recruiting
NCT01470209 Phase I Buparlisib + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed
NCT03919292 Phase Ib/II Divalproex sodium + Neratinib Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Recruiting
NCT02610361 Phase I BGB-283 Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed
NCT03051035 Phase I KO-947 First-in-Human Study of KO-947 in Non-Hematological Malignancies Recruiting
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Completed
NCT01624467 Phase II Necitumumab A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors Completed
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Recruiting
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Recruiting
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03190915 Phase II Trametinib Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Recruiting
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn
NCT02140840 Phase II Trametinib A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Withdrawn
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed
NCT01933932 Phase III Docetaxel + Selumetinib Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC Active, not recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT01138085 Phase I Trametinib + Uprosertib Safety, Pharmacokinetics (PK) of AKT and MEK Combination Completed
NCT01971515 Phase I M2698 First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies Completed
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed
NCT01783197 Phase I Selumetinib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Completed
NCT02134886 Phase I Erlotinib Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection Terminated
NCT01274624 Phase I Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Reolysin Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Completed
NCT01833143 Phase II Bortezomib Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Active, not recruiting
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting
NCT03181100 Phase II Nab-paclitaxel Paclitaxel Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Recruiting
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02285439 Phase Ib/II Binimetinib Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors Recruiting
NCT03170206 Phase Ib/II Palbociclib Binimetinib Binimetinib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Recruiting